Avandia Lawsuit

The biggest drug making company in the United Kingdom announced in January 2011 that fourth quarter legal costs would hit the $3.5 billion. This undertaking was prompted by the commencement of US government investigations into claims of bad practice during the sale of Avandia diabetes drug and other related products.

GlaxoSmithKline plc was particularly concerned about the decision by the Colorado attorney to investigate the behavior of the company as it promoted its products and services. According to reliable sources, this new injection of legal cover brought to about 4 billion pounds the amount of money the company has used in 2010 alone. According to a London based analyst working with Matrix Corporate Capital LLP, this amount for a legal cost is outrageous, although some additional charge was expected. The instant result of this new charge was a change in the capital market where at the end of trading, shares fell from an earlier gain of 1.4% to a loss of 1.6%.

Reports of a possible withdrawal of Avandia from the market came in September 2010 after there were reports of reduced marketing of the drug in the world market. Avandia was once the most popular diabetes drug, but this reputation was immensely affected by the realization that it increased risks of heart attacks. The decision to use a significant charge though argued to be for the company’s interest, would have an impact on the overall earnings, according to analysts. In fact, analysts had foretold a loss in the firm given that after tax value of expenses was 1.8billion pounds while the estimated earnings for the same period was 1.44billion pounds.

The Colorado Avandia lawsuit was also costly to the firm; costs relating to the Colorado investigation in the fourth quarter of 2008 were 278 million pounds. The case took a nationwide aspect when investigators started looking into claims of alleged influence of medical personnel, though the products under investigation were still unknown by then.

In a statement released after the commencement of the huge charge, Mr. PD Villarreal, who was a senior member of the litigation team, agreed that the charge was significant but the legal matters facing the company gave the management no other choice. He also noted that the company had succeeded in concluding several high profile cases in the previous years, so there was hope the litigation risk would be lowered. However, the number of Avandia lawsuits yet to be closed remains unknown.